KalVista Pharmaceuticals (KALV) Enterprise Value (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Enterprise Value of -$191.5 million in Q3 2025, up 13.21% quarter-over-quarter from -$220.6 million in Q2 2025, and down 9.87% year-over-year from -$212.4 million in Q3 2024.
KalVista Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$191.5 million for Q3 2025.
- In Q3 2025, Enterprise Value fell 9.87% year-over-year to -$191.5 million; the TTM figure through Jul 2025 stood at -$191.5 million (down 9.87% YoY), while the FY2025 annual figure was -$220.6 million, down 4.86% from the prior year.
- Enterprise Value came in at -$191.5 million for Q3 2025 at KalVista Pharmaceuticals, up from -$220.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$50.3 million in Q1 2021 to a low of -$268.3 million in Q4 2024.
- A 5-year average of -$167.8 million and a median of -$171.7 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value sank 287.17% in 2022 and surged 55.97% in 2024, its largest moves.
- KalVista Pharmaceuticals' Enterprise Value stood at -$209.8 million in 2021, then jumped by 41.72% to -$122.3 million in 2022, then advanced by 15.62% to -$103.2 million in 2023, then plunged by 160.09% to -$268.3 million in 2024, then climbed by 28.65% to -$191.5 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$191.5 million, -$220.6 million, and -$268.3 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -191.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -191.47 Mn |
| Apr 30, 2025 | -220.62 Mn |
| Dec 31, 2024 | -268.35 Mn |
| Oct 31, 2024 | -135.78 Mn |
| Jul 31, 2024 | -174.27 Mn |
| Apr 30, 2024 | -210.40 Mn |
| Jan 31, 2024 | -75.59 Mn |
| Oct 31, 2023 | -103.17 Mn |
| Jul 31, 2023 | -123.26 Mn |
| Apr 30, 2023 | -149.38 Mn |
| Jan 31, 2023 | -171.69 Mn |
| Oct 31, 2022 | -122.27 Mn |
| Jul 31, 2022 | -142.08 Mn |
| Apr 30, 2022 | -166.20 Mn |
| Jan 31, 2022 | -194.79 Mn |
| Oct 31, 2021 | -209.81 Mn |
| Jul 31, 2021 | -230.63 Mn |
| Apr 30, 2021 | -248.93 Mn |
| Jan 31, 2021 | -50.31 Mn |
| Oct 31, 2020 | -55.87 Mn |
| Jul 31, 2020 | -64.33 Mn |
| Apr 30, 2020 | -67.71 Mn |
| Jan 31, 2020 | -80.57 Mn |
| Oct 31, 2019 | -93.46 Mn |
| Jul 31, 2019 | -100.37 Mn |
| Apr 30, 2019 | -100.81 Mn |
| Jan 31, 2019 | -111.15 Mn |
| Oct 31, 2018 | -121.12 Mn |
| Jul 31, 2018 | -48.07 Mn |
| Apr 30, 2018 | -51.06 Mn |
| Jan 31, 2018 | -58.68 Mn |
| Oct 31, 2017 | -28.13 Mn |
| Jul 31, 2017 | -26.46 Mn |
| Apr 30, 2017 | -30.95 Mn |
| Jan 31, 2017 | -33.50 Mn |
| Oct 31, 2016 | -10.69 Mn |
| Jul 31, 2016 | -15.63 Mn |
| Mar 31, 2016 | -48.59 Mn |
| Dec 31, 2015 | -53.72 Mn |
| Sep 30, 2015 | -59.88 Mn |
| Jun 30, 2015 | -65.38 Mn |
| Mar 31, 2015 | -3.18 Mn |
| Dec 31, 2014 | -3.90 Mn |
| Sep 30, 2014 | -9.33 Mn |
| Jun 30, 2014 | -7.18 Mn |
| Mar 31, 2014 | -9.28 Mn |